Bradykinin-forming components in Kuwaiti patients with type 2 diabetes

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 3, 2013, Pages 699-705

  Sharma, J N ^a   Al Shoumer, K A S ^a   Matar, K M ^a   Al Gharee, H Y ^b   Madathil, N V ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b General Clinic   (Kuwait)

Author keywords

Diabetic patients; Healthy subjects; Plasma kallikrein; Plasma kininogen; Plasma prekallikrein; Tissue kallikrein

Indexed keywords

BRADYKININ; HEMOGLOBIN A1C; KALLIKREIN; KININOGEN; PREKALLIKREIN; TISSUE KALLIKREIN;

ADULT; ARAB; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KALLIKREIN URINE LEVEL; KALLIKREINOGEN BLOOD LEVEL; KININOGEN URINE LEVEL; KUWAIT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN URINE LEVEL; RENAL PROTECTION; RISK FACTOR; TISSUE KALLIKREIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BRADYKININ; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KALLIKREINS; KININOGENS; KUWAIT; MALE; TISSUE KALLIKREINS;

EID: 84887491907     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600313     Document Type: Article

References (24)

1. Leeb-Lundberg LMF, MarceauF, Muller-EsterlW,Pettibone DJ, Zuraw BL. Classification of the kinin receptor family: From Molecular mechanisms to Pathophysiological consequences. International Union of Pharmacology. XLV. Pharmacol Rev 2005; 57:27-77. (Pubitemid 40283969)
2. Abdella N, Arouj M, AlNakhi A, Al Assoussi A, Moussa M. Non-insulin- dependent diabetes in Kuwait: prevalence rates and associated risk factors. Diabetes Res Clin Pract 1998; 42:187-96. (Pubitemid 29009780)
3. Al-Shoumer KA, Al-Asoosi A, Doi S, Vasanthy BA. Serum leptin and metabolic variables in Arabs with type 2 diabetes. Ann Saudi Med 2008; 28:367-70.
4. Sharma JN, Narayanan P. Hypertension and diabetes: Contribution of kallikrein-kinin system. Diabetes Metabolism 2011; S4:1-5.
5. Rabito SF, Scicli AG, Kher V, Carretero OA. Immunoreactive glandular kallikrein in rat plasma: a radioimmunoassay for its determination. Am J Physiol 1982; 242:H602-10.
6. Yayami M, Kunimatsu N, Teranishi Y, Takano M, Okamoto H. Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 2003; 1593:231-8. (Pubitemid 36173491)
7. Katori M, Majima M. A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci 2006; 100:370-90. (Pubitemid 44609529)
8. Sharma JN, Uma K, Yusof AP. Left ventricular hypertrophy and its relation to cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 1998;63:229-35. (Pubitemid 28150000)
9. Sharma JN, Uma K, Noor AR, Rahman AR. Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996; 27:55-63. (Pubitemid 26076849)
10. Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH, DCCT/EDIC Study Group. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 2003; 52:1215-21. (Pubitemid 36523359)
11. Harvey JN, Jaffa AA, Margolius HS, Mayfield RK. Renal kallikrein and the hemodynamic abnormalities of the diabetic kidney. Diabetes 1990; 39:299-304. (Pubitemid 20076212)
12. Jaffa AA, Rust PF, Mayfield RK. Kinin, a mediator of diabetes induced glomerular hyperfiltration. Diabetes 1995; 44:156-60.
13. Parappil A, Doi SAR, Al-Shoumer KAS. Diagnostic criteria for diabetes revisited: making use of combined criteria. BMC Endocrinol Disorders 2002; 2:1-7.
14. Domke I, Cremer P, Huchtemann M. Therapeutic drug monitoring on COBAS INTEGRA 400 - evaluation results. Clin Lab 2000; 46:509-15.
15. Jaffa AA, Miller DH, Bailey GS, Chao J, Margolius HS. Abnormal regulation of renal kallikrein in experimental diabetes. J Clin Invest 1987; 80:1651-9.
16. Jaffa AA, Vio CP, Velarde V, LeRoith D, Mayfield R. Renal kallikrein and renin mRNA levels in diabetes and their induction by insulin and insulin like growth factor 1. Diabetes 1997; 46:2040-56.
17. Sharma JN, Kesavarao U. Changes in plasma prekallikrein, blood pressure and left ventricular thickness in hypertensive and normotensive diabetic rats. Methods Find Exp Clin Pharmnacol 2007; 29:75-8. (Pubitemid 46797625)
18. Weinberg MS, Trebbin WM, Solomon RJ. Urinary kininogen: a possible regulator of kinin formation in normal individuals and subjects with essential hypertension, end-stage renal and liver disease. Adv Exp Med Biol 1986; 198A:119-25.
19. Weinberg MS, Azar P, Trebbin, et al. The role of urinary kininogen in regulation of kinin generation. Kidney Int 1985; 28:975-81. (Pubitemid 16148402)
20. Zuccollo A, Navarro M, Catanzero O. Effect of B1 aqnd B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 1996; 74:586-9. (Pubitemid 26341482)
21. Meng K, Haberland GL. In: Haberland, Rohen JW, eds. Kininogenases Kallikrein. F.K. SchattauerVerlag, Stuttgart, New York, 1973; 75-80.
22. Campbell DJ, Kladis A, Zhang Y, et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010; 53:779-85.
23. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang Z, Chao L. Tissue kallikrein elicits cardio protection by direct kinin B2 receptor activation independent of kinin formation. Hypertension 2008; 52:715-20.
24. Christopher J, Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2002; 2:1771-9. (Pubitemid 35373920)